Clinical applications of FDG-PET in oncology

被引：28

作者：

Czernin, J ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Ahmanson Biol Imaging Clin, Los Angeles, CA 90024 USA

来源：

ACTA MEDICA AUSTRIACA | 2002年 / 29卷 / 05期

关键词：

positron emission tomography; oncology; FDG;

D O I：

10.1046/j.1563-2571.2002.02042.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Positron emission tomography together with F-18-deoxyglucose (FDG) has emerged as a valuable clinical tool in the field of oncology. FDG-PET diagnoses, stages and restages most cancers with a high diagnostic accuracy. The effects of chemotherapy on tumour metabolism can be monitored with this whole-body technique. Recent studies have established a high prognostic accuracy of PET for predicting the clinical outcome of cancer patients. The current review addresses the role of FDG-PET for diagnosing, staging and restaging of lung cancer, colorectal cancer, lymphoma, melanoma and breast cancer staging and provides a brief outlook for future applications of clinical PET imaging.

引用

页码：162 / 170

页数：9

共 94 条

[1] Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer [J].